logo of the EU drugs agency

You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.


Drug-related infectious diseases

This area develops indicators for more reliable and comparable monitoring of hepatitis B/C and HIV in injecting drug users. This is necessary for identifying priorities for preventing further infections, for forecasting health-care needs and costs, and for monitoring the impact of preventive interventions.


Prevalence of HIV, HCV and HBV in IDUs

Tables INF-1, INF-2 and INF-3 provide a summary overview of latest available data on HIV, HCV and HBV prevalence in samples of injecting drug users.

Tables INF-108, INF-109 and INF-110 show full data on HIV prevalence in samples of injecting drug users, as well as prevalence among young injectors and new injectors for HIV. Table INF-18 shows trends in HIV prevalence in selected countries (with average prevalence above 5 %).

Tables INF-111, INF-112 and INF-113 show full data on HCV prevalence in samples of injecting drug users as well as prevalence among young injectors and new injectors for HCV. Table INF-19 shows trends in HCV prevalence in selected countries (with average prevalence above 50 %).

Tables INF-114 and INF-115 show full data on prevalence of HBV current infection (HBsAg) and of HBV antibodies (aHBc, aHBs), respectively. Table INF-117 shows prevalence of infectious diseases among drug users in prison. Part (i) shows prevalence of HIV infection, part (ii) of hepatitis C infection, part (iii) of HBsAg marker of current hepatitis B infection and part (iv) of hepatitis B antibodies.

Figures INF-6 and INF-9 show trend data on prevalence of hepatitis C and B, respectively.

Figure INF-3 shows HIV prevalence in all injectors ( part (i)) and young injectors ( part (ii)).

HIV case reporting and hepatitis B/C notifications

Figures INF-1 and INF-2 show AIDS and HIV case reporting data, respectively.

Tables INF-104, INF-105 and INF-106 show counts of case reports or notifications of newly diagnosed HIV, HCV and HBV cases, respectively. The HIV case reports, provided by EuroHIV, are also expressed as rates per million population. For hepatitis notifications, rates per million are not calculated, given the likely low comparability of figures between countries. Tables INF-105 and INF-106 also give the percentage of IDUs among the cases of hepatitis C and B that have information on the presumed transmission category.

Table INF-107: a small number of countries report incidence data for HCV from follow-up studies of IDUs at mostly sub-national level. Table INF-107 reports the number of IDUs followed, the number of sero-conversions, follow-up time, the incidence rate per 100 person-years.

Table INF-0 lists all bibliographic references.

The table below summarises the overall organisation of the core set of tables and graphs.


Hepatitis C

Hepatitis B

Prevalence – latest data

Table INF-1 and Figure INF-3

Table INF-2 and Figure INF-6

Table INF-3 and Figure INF-9

Prevalence – time trends

Table INF-108

Table INF-111

Table INF-115

Case reports/notifications

Table INF-104, Figure INF-1 and Figure INF-2

Table INF-105

Table INF-106